The Democrats are back on top in the House and Senate after more than a decade playing second fiddle to the GOP. Although health reform was not a prime issue moving votes this November, health policy is on the Democrats' "100 hours" to-do list.
The Democrats are back on top in the House and Senate after more than a decade playing second fiddle to the GOP. Although health reform was not a prime issue moving votes this November, health policy is on the Democrats' "100 hours" to-do list.
The savings from government price negotiating theoretically would provide funds to fill in the much-maligned "donut hole" in Part D, which is just now hitting thousands of seniors. Funding to support a more comprehensive Medicare drug benefit also could come from new payroll taxes on workers and employers, or Congress may push to expand imports of low-cost drugs to help cut drug costs overall.
Another Democratic target will be Medicare payments to private plans. The shift in control of Congress puts long-time industry critic Rep. Pete Stark (D-Calif.) at the helm of the House Ways and Means Heath subcommittee. Stark has long complained that Medicare pays private plans too much money and is planning hearings and investigations into the Medicare Advantage program and managed care. At the same time, Stark says he doesn't want new Medicare legislation for fear of killing the whole drug benefit, but plans to attack a range of issues such as drug pricing, private plans and government waste and fraud.
Stark's position reflects a major shift in political philosophy at the powerful subcommittee, which oversees tax policy and Medicare and Medicaid spending. Liberal Democrat Charles Rangel of New York replaces conservative Bill Thomas (R-Calif.) as Ways and Means chairman. And Stark takes over from Nancy Johnson of Connecticut, who lost her re-election bid.
In addition, Rep. John Dingell (D-Mich.) returns to the helm of the House Energy and Commerce Committee, a prime platform for criticizing administration health policy and pressing for changes in the Part D drug benefit. Similarly, Rep. Henry Waxman (D-Calif.) will step up investigations of health and pharmaceutical issues as chair of the House Government Reform Committee.
The debate on health issues promises to be less contentious in the Senate, where the Democrats' narrow majority will require bipartisan cooperation to move legislative initiatives. Sen. Ted Kennedy (D-Mass.) takes the helm of the Health, Education, Labor and Pensions (HELP) Committee, but has a good working relationship with the top Republican, Sen. Mike Enzi of Wyoming. The Senate Finance Committee will be headed by Sen. Max Baucus of Montana, who has worked closely with former chairman Sen. Charles Grassley of Iowa. They will continue to focus on Medicare and Medicaid and investigate healthcare spending and related tax issues.
Jill Wechsler, a veteran reporter, has been covering Capitol Hill since 1994.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More